Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fortress Biotech (FBIO) Change in Receivables: 2016-2024

Historic Change in Receivables for Fortress Biotech (FBIO) over the last 9 years, with Dec 2024 value amounting to -$4.5 million.

  • Fortress Biotech's Change in Receivables rose 175.37% to $2.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.8 million, marking a year-over-year increase of 98.23%. This contributed to the annual value of -$4.5 million for FY2024, which is 64.35% up from last year.
  • As of FY2024, Fortress Biotech's Change in Receivables stood at -$4.5 million, which was up 64.35% from -$12.6 million recorded in FY2023.
  • Over the past 5 years, Fortress Biotech's Change in Receivables peaked at $10.4 million during FY2020, and registered a low of -$12.6 million during FY2023.
  • In the last 3 years, Fortress Biotech's Change in Receivables had a median value of -$4.5 million in 2024 and averaged -$3.9 million.
  • As far as peak fluctuations go, Fortress Biotech's Change in Receivables soared by 800.52% in 2022, and later crashed by 333.29% in 2023.
  • Yearly analysis of 5 years shows Fortress Biotech's Change in Receivables stood at $10.4 million in 2020, then tumbled by 107.36% to -$768,000 in 2021, then spiked by 800.52% to $5.4 million in 2022, then tumbled by 333.29% to -$12.6 million in 2023, then spiked by 64.35% to -$4.5 million in 2024.